BMN 333
Alternative Names: BMN-333; C-type natriuretic peptide; Long acting C-type natriuretic peptide (CNP); Long acting CNP - BioMarin PharmaceuticalsLatest Information Update: 07 Sep 2023
At a glance
- Originator BioMarin Pharmaceutical
- Class Natriuretic peptides
- Mechanism of Action Natriuretic peptide replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders; Musculoskeletal disorders
Most Recent Events
- 22 Jun 2023 Preclinical trials in Metabolic disorders in USA (Unspecified) (BioMarin Pharmacetical pipeline, June 2023)
- 22 Jun 2023 Preclinical trials in Musculoskeletal disorders in USA (Unspecified) (BioMarin Pharmacetical pipeline, June 2023)